With your own knowledge and the help of the following document:

Document 1 (Title: Malabsorption and Vitamin Deficiencies in Cystic Fibrosis): Cystic fibrosis (CF) represents an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride channel essential for epithelial fluid transport. While pulmonary manifestations typically dominate the clinical picture, pancreatic insufficiency affects approximately 85% of patients and contributes to significant nutritional complications. The pathophysiological cascade begins with defective chloride and bicarbonate secretion into the pancreatic ducts, resulting in reduced fluid volume and increased viscosity of pancreatic secretions. This leads to ductal obstruction, acinar cell damage, and ultimately fibrosis with progressive loss of exocrine function. Consequent deficiency of pancreatic enzymes, particularly lipase, causes maldigestion and malabsorption of dietary fat and fat-soluble vitamins (A, D, E, and K). Vitamin K deficiency merits particular attention due to its essential role in post-translational modification of coagulation factors II, VII, IX, and X. These vitamin K-dependent factors require gamma-carboxylation of glutamic acid residues for calcium binding and functional activity. In the absence of adequate vitamin K, undercarboxylated factors (PIVKA - Proteins Induced by Vitamin K Absence) accumulate, resulting in coagulopathy characterized by prolonged prothrombin time (PT) while activated partial thromboplastin time (aPTT) remains relatively normal. This pattern distinguishes vitamin K deficiency from other coagulopathies such as disseminated intravascular coagulation or liver synthetic dysfunction. Unlike vitamin A deficiency, which may manifest as corneal xerosis and night blindness, or vitamin B1 deficiency associated with Wernicke's encephalopathy, vitamin K deficiency remains clinically silent until challenged by hemostatic stress such as surgery or trauma.
Document 2 (Title: Coagulation Defects in Young Women with Menorrhagia): Menorrhagia, defined as excessive menstrual bleeding lasting more than 7 days or exceeding 80 mL per cycle, affects approximately 10-30% of women of reproductive age, with a significant proportion attributable to underlying bleeding disorders. When persistent since menarche and accompanied by other mucocutaneous bleeding manifestations, inherited coagulation disorders warrant particular consideration. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects approximately 1% of the general population and accounts for up to 20% of unexplained menorrhagia cases in otherwise healthy women. VWD results from quantitative or qualitative deficiencies in von Willebrand factor (VWF), a large multimeric glycoprotein that mediates platelet adhesion to subendothelial collagen and serves as a carrier for factor VIII. This autosomal inheritance pattern leads to equal sex distribution, contrasting with the X-linked recessive inheritance of hemophilia A, which primarily affects males. Laboratory evaluation of VWD typically reveals prolonged activated partial thromboplastin time (aPTT) due to secondary factor VIII deficiency, while prothrombin time (PT) and platelet count remain normal. Patients typically present with mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, and particularly menorrhagia in women. Family history often reveals similar bleeding tendencies in first-degree relatives of both sexes, contrasting with the maternal uncle pattern in hemophilia A or the prothrombotic tendencies in conditions like protein C deficiency or antiphospholipid syndrome.
Document 3 (Title: Genetic Determinants of Lipoprotein Metabolism and Vascular Disease): High-density lipoprotein cholesterol (HDL-C) represents a complex, heterogeneous lipoprotein fraction historically associated with cardioprotective effects, though the causal nature of this relationship has been increasingly questioned. While epidemiological studies consistently demonstrate inverse associations between HDL-C levels and cardiovascular disease (CVD) risk, genetic studies and therapeutic trials targeting HDL-C have yielded inconsistent results, suggesting more complex relationships than initially proposed. Mutations causing low HDL-C occur through various mechanisms, predominantly affecting apolipoprotein A-I (the principal HDL protein component), ATP-binding cassette transporter A1 (ABCA1, mediating cellular cholesterol efflux), lecithin-cholesterol acyltransferase (LCAT, catalyzing cholesterol esterification), or cholesteryl ester transfer protein (CETP, facilitating lipid exchange between lipoproteins). These genetic variants produce distinct HDL particle compositions beyond simply reduced cholesterol content, potentially explaining divergent clinical manifestations. Surprisingly, detailed phenotypic characterization of subjects with genetically determined low HDL-C has not consistently demonstrated the accelerated atherosclerosis predicted by epidemiological associations. Particularly compelling evidence comes from studies of ABCA1 mutation carriers (Tangier disease), who despite profoundly reduced HDL-C levels, demonstrate only modestly increased cardiovascular risk. Similarly, LCAT deficiency, while producing dramatic HDL reduction, shows inconsistent associations with premature atherosclerosis. Even apoA-I mutations, affecting the structural protein of HDL, demonstrate variable vascular phenotypes not consistently correlating with HDL-C reduction magnitude. Contemporary mechanistic research suggests HDL functionality—its capacity to promote reverse cholesterol transport, exert anti-inflammatory effects, and maintain endothelial function—may be more relevant to cardiovascular protection than absolute HDL-C concentration. This functionality appears partially independent of HDL-C levels, explaining apparent discrepancies between epidemiological associations and genetic studies. Subclinical atherosclerosis assessment through carotid intima-media thickness (cIMT) measurement has been particularly informative, with multiple studies specifically examining the relationship between genetically determined low HDL-C and vascular structure. These investigations consistently demonstrate that isolated genetic causes of low HDL-C without accompanying metabolic perturbations do not significantly increase cIMT compared to controls, contradicting predictions based solely on HDL-C levels. This dissociation between HDL-C concentration and vascular phenotype has profound implications for therapeutic approaches targeting HDL, suggesting intervention efficacy may depend on functional improvements rather than simple quantitative HDL-C elevation.

Answer the following multiple-choice question.
Question: A 27-year-old female presents to general medical clinic for a routine checkup. She has a genetic disease marked by a mutation in a chloride transporter. She has a history of chronic bronchitis. She has a brother with a similar history of infections as well as infertility. Which of the following is most likely true regarding a potential vitamin deficiency complication secondary to this patient's chronic illness?
Options:
A. It may result in corneal vascularization
B. It may result in the triad of confusion, ophthalmoplegia, and ataxia
C. It may be exacerbated by excessive ingestion of raw eggs
D. It may manifest itself as a prolonged PT

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ← if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.